Disulfiram (Tetraethylthiuram Disulfide) in the Treatment of Lyme Disease and Babesiosis: Report of Experience in Three Cases

Kenneth B Liegner

doi:10.3390/antibiotics8020072

Disulfiram (Tetraethylthiuram Disulfide) in the Treatment of Lyme Disease and Babesiosis: Report of Experience in Three Cases

Antibiotics (Basel). 2019 May 30;8(2):72. doi: 10.3390/antibiotics8020072.

Author

Kenneth B Liegner^{1

2

3}

Affiliations

¹ 592 Route 22-Suite 1B, Pawling, NY 12564, USA. kbliegnermd@optonline.net.
² Northwell System, Northern Westchester Hospital, Mount Kisco, NY 10549, USA. kbliegnermd@optonline.net.
³ Health Quest System, Sharon Hospital, Sharon, CT 06069, USA. kbliegnermd@optonline.net.

Abstract

Three patients, each of whom had required intensive open-ended antimicrobial therapy for control of the symptoms of chronic relapsing neurological Lyme disease and relapsing babesiosis, were able to discontinue treatment and remain clinically well for periods of observation of 6-23 months following the completion of a finite course of treatment solely with disulfiram. One patient relapsed at six months and is being re-treated with disulfiram.

Keywords: Chronic Lyme disease; Post-treatment Lyme disease syndrome (PTLDS); antibiotic treatment failure; disulfiram; neuroborreliosis; persistent infection; relapsing babesiosis.